US · Healthcare · Medical Devices
EPS came in at -0.24 against a street estimate of -0.32 — a beat of 25.0%.
Analysts rate Clearpoint Neuro Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $23.50.
MIXED ClearPoint delivered strong Q3 revenue growth and capital placements, while margins declined and cash burn remains material as it invests in CAL, IRRAflow, robotics and focused ultrasound. Q3 FY26 Analysts pressed management on 2027 catalysts, cash burn, spine LITT economics and regulatory requirements. Management emphasized AMT-130, Phase III site expansion, declining operating burn and staged clinical development. 2026-10-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.80% |
| Mak Capital One LLC | 7.79% |
| Vanguard Capital Management, LLC | 4.04% |
| State Street Corp | 2.68% |
| Geode Capital Management, LLC | 2.46% |
| Lane Generational LLC | 1.46% |
| UBS Group AG | 1.41% |
| Millennium Management LLC | 1.17% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Clearpoint Neuro Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.